Re2O (hADM) in Daegu — what it places, and what was observed
Most boosters send the skin a signal to make collagen. hADM is different — it leaves the dermis’s own building material in that layer. Here is what that rests on, and how we design the injection by area.
The short answer
Re2O (hADM) is not a material that signals — it is a material that is placed. Most boosters tell the skin “make collagen”; hADM leaves the dermis’s own building material in that layer. This article sets out what that idea actually rests on — what animal histology showed, what the human study found, and how we design the injection by area.
What animal histology showed
In a study placing injectable hADM under mouse dorsal skin and examining tissue at 2, 4, 8, 12 and 24 weeks, three things were seen at the injection site.
- Fibroblasts move in. The placed matrix does not simply occupy space — surrounding cells migrate into it.
- New vessels form. Vascular ingrowth means the structure is joining the tissue rather than sitting apart from it.
- The capsule forms thin. A material that drives a strong foreign-body reaction produces a thick capsule; here it was thin.
That is the substance behind the phrase “it acts as a scaffold.” It is animal histology, and whether the same happens in human facial dermis is still to be established — we state that distinction as it is.
What was shown in people — the split-face study
Re2O has a split-face double-blind randomised study from Severance Hospital, Yonsei University (Int J Mol Sci 2026;27(5):2193 / NCT07155278). Re2O went into one side of the face and hyaluronic acid into the other, with measurements at baseline and weeks 1, 4, 8, 12, 16 and 20.
The design is the strength here. Comparing the left and right of the same person means age, skin thickness and lifestyle cancel out, and the double blind reduces the chance that an assessor’s expectation colours the reading.
What was reported was significant difference in skin density, volume, wrinkle depth, pore appearance, hydration and elasticity, with no serious adverse events. The paper does not name the product; identity was confirmed against the trial registration number (NCT07155278).
What “long used in surgery” does and does not carry
hADM has a long history in reconstructive surgery — in burns, wounds and breast reconstruction, in sheet form. Placing it as an injectable into the dermis is a different use, and we keep the two apart when we explain it.
What the surgical record carries is the character of the material: a matrix stripped of cells and DNA, which is why the risk of a rejection response is low even though it came from another person. What it does not carry is the result and the duration in an aesthetic treatment. That is why we do not use phrases like “lasts so many months.”
Being human tissue — it means the record follows it
Re2O is handled as human tissue rather than as a medical device. What that status actually means is that the record follows the material.
- Donation, processing, testing, storage and distribution are recorded end to end — tighter, in fact, than for synthetic-polymer classes.
- Safety is managed in layers: donor screening and serology, viral inactivation during processing, and the decellularisation step that removes cell antigens and DNA.
- Distribution and implantation are prohibited by law in defined cases — transmissible infection, or an undetermined cause of death, among others.
We tell you the origin before the decision, not after, and if it does not sit right with you we do not press it. There are other classes for the same goal.
How we design it at Miso Clinic
- The layer is the dermis. This is not a material that builds volume underneath — it leaves the skin’s own material in that layer.
- In thin areas we reduce the volume and increase the points. Facial skin thickness varies widely by area (3D scanner study: 2.1 ± 0.4 mm, a standard deviation 36% of the mean), and how many points the dose is divided across affects the result more than the total.
- Sessions go by condition, not the calendar. We start on three sessions a month apart and decide on more from how it has settled.
- There is no reversal injection. hADM is not hyaluronic acid, so hyaluronidase does not dissolve it — though it is a material the body breaks down, so it does not stay permanently. We therefore start short and add later.
- We give you a contact threshold. Pain in one spot lasting more than two days, a change in colour, or swelling that grows again means call us rather than wait.
Frequently asked questions
What most separates Re2O from other boosters?
What it places. Most boosters send the skin a signal to make collagen; hADM leaves the dermis’s own building material in that layer. It is the difference between signalling and supplying.
What was actually observed behind “it acts as a scaffold”?
In animal histology, fibroblasts migrating into the injection site, new vessels forming, and a thin capsule. A material that drives a strong foreign-body reaction produces a thick capsule; here it was thin. Confirmation in human facial dermis is still to come.
What was shown in people?
A split-face double-blind randomised study at Severance Hospital, Yonsei University. Re2O on one side and hyaluronic acid on the other, compared over 20 weeks, reporting significant difference in skin density, volume, wrinkle depth, pores, hydration and elasticity, with no serious adverse events. Comparing the same person’s two sides cancels out individual variation.
It has been used in surgery for years — is that reassuring?
What the surgical record carries is the character of the material — a matrix stripped of cells and DNA, so the risk of a rejection response is low. What it does not carry is the result and duration in an aesthetic treatment, and injectable use differs from sheet use. We keep the two apart.
How long does it last?
We do not use phrases like “lasts so many months.” We start on three sessions a month apart and decide on more by condition rather than by the calendar.
Can it be reversed?
Hyaluronidase does not dissolve it — it is not hyaluronic acid. It is, though, a material the body breaks down, so it does not stay permanently. Because there is no reversal injection, we start short and add later.
The human origin of the material bothers me.
We do not press it — there are other classes for the same goal. What we will say is that being human tissue means donation, processing, testing, storage and distribution are all recorded, and safety is managed in layers through donor screening, viral inactivation and decellularisation.
Read next
Who wrote this
Written and reviewed by Lee Chi-Hak, MD, director of Miso Clinic, Daegu. The treatment standards and injection design here are the ones we use in practice.
4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, Korea (Exit 1, Kyungpook National University Hospital Station)
+82-53-428-2700 · www.clinicmiso.co.kr
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.
← Clinical columns · Reference library · Miso Clinic Daegu
한국어 · English